Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and ...
Granted FDA Breakthrough designation, CardiAMP Cell Therapy uses a patient’s own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure intended to increase ...
MediBeacon’s CEO, Steven Hanley, will present at the upcoming Stifel Healthcare Conference in New York on Tuesday, Nov. 11, 2025 at 5:40 AM PST / 8:40 AM EST. Media and Investor Contact Carrie ...
Evaxion expects to accumulate an operational cash spend of $14 million in 2025. By the end of the second quarter 2025, Evaxion had cash at hand of $14.7 million. We have since had a gross inflow of ...
Listen-Only Webcast The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on ...
About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, ...
Tilray’s participation in the American Craft Beer Experience Festival in Japan underscores the company’s commitment to growing its beverage business across key global markets, especially in Asia, ...
The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study evaluating single and multiple ascending doses of FT2109 in healthy adult volunteers. The trial will assess the ...
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and ...
A recording of this presentation will be made available on the company website. In addition, Biodesix executives, scientists, and expert consultants will be present at booth #647 to discuss Biodesix ...
Ian Farnan, CEO, said, “We are excited to welcome someone with Alistair’s commercial and financial experience to the Board of Cambridge Atomworks. His expertise and knowledge will be invaluable as ...
Renal Cell Carcinoma (RCC): FDA approved oral Everolimus for advanced RCC after failure of sunitinib and/or sorafenib. Approval was based on RECORD-1 randomized phase III (everolimus 10 mg PO daily vs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback